

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 25, 2025**

NEXGEL, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	001-41173 (Commission File Number)	26-4042544 (IRS Employer Identification No.)
2150 Cabot Boulevard West, Suite B Langhorne, Pennsylvania (Address of principal executive offices)		19067 (Zip Code)

Registrant's telephone number, including area code: **(215) 702-8550**

(Former name or former address, if changed since last report)

Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001	NXGL	The Nasdaq Capital Market LLC
Warrants to Purchase Common Stock	NXGLW	The Nasdaq Capital Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On March 25, 2025, NexGel, Inc. began utilizing a new investor presentation, a copy of which is attached hereto as Exhibit 99.1.

The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "*Exchange Act*"), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	NexGel, Inc. Investor Presentation, dated March 2025.
104	Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 25, 2025

NEXGEL, INC.

By: /s/ Adam Levy
Adam Levy
Chief Executive Officer



Investor Presentation

March 2025



NASDAQ: NXGL

Forward-Looking Statement

This presentation contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature.

Additional written and oral forward-looking statements may be made by the Company from time to time in filings with the Securities and Exchange Commission (SEC) or otherwise.

The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms.

These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC.

Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. Except as otherwise required by law, the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.



NASDAQ: NXGL

NEXGEL – Who We Are and What We Do

After two decades of creating custom hydrogel solutions for large medical device companies, our business today includes the development of patented medical devices, custom/white label products, and OTC healthcare consumer products.

We invested in our in-house converting and packaging capabilities to better meet our customer's evolving needs.

These strategic growth opportunities reflect our dedication to pioneering advancements across various domains, delivering great value to our customers and stakeholders.

Agreements with Multi-Billion Dollar Corporations




abbvie



Medtronic

Multiple Products & Applications for Nexgel's Technology



Competitive Advantage: 1 of 2 State-of-the-Art Manufacturing Facilities in NA

Medical grade technology and facility, providing gels to multi-national device companies for over 20 years with sufficient capacity to fulfill consumer and healthcare segments

1 of 2 manufacturing facilities in North America that can produce state-of-the-art hydrogel transdermal products
– successfully used 200+ different active ingredient combinations to date

16,500-square-ft GMP
13,500-square-ft manufacturing space

>1.4 Billion square inches of product per year is total capacity

Electron Beam Accelerator eliminates the need for harmful chemicals in hydrogel production

3,000-square-ft office space

Sufficient capacity across healthcare and consumer divisions

High barrier to entry for new facilities (2+ yrs to go live)

Stringent compliance requirements

Technical expertise needed to operate



NASDAQ: NXGL



5

Converting and Packaging Facility

50% ownership in converting and packaging business in Granbury, Texas

- Significant synergies which enable the onboarding of potential finished goods customers along with enhanced combined marketing and outreach efforts
- Increased square footage and installed cutting-edge automated machinery in our clean room facilities to support anticipated growth
- CG Labs converting and packaging division is one of NEXGEL's largest customers



NASDAQ: NXGL

Hydrogels for Consumer and Medical Applications

- Electron beam technology eliminates the need for harmful chemicals in cross-linking, which, along with our paraben-free formulation, makes our patches the only option for many medical device applications and preferred among consumers
- Gentle formulation & strong adhesion properties eliminates many problems with existing transdermal devices & dermal interfaces such as:
 - Deterioration of skin integrity
 - Skin allergies
 - Skin irritation
 - Discomfort
 - Skin tears
 - Removal of dermis
 - Pain

All of these contribute to increased risk of infection and overall patient dissatisfaction

Current Medical Device Pipeline

Addressing the importance of skin integrity and overall skincare with a medical device

Medical Device Pipeline: Drug Delivery

Potential for Multiple Drug Delivery Applications through Unique Hydrogel Technology

Drug Delivery: Diclofenac Patch


To treat short-term pain due to preclinical sprains and bruises

Drug Delivery: Apremilast Patch

To treat autoimmune conditions, such as arthritis and psoriasis

- Promising pre-clinical human results (12 patients)
- Proof-of-concept study completed, validating the potential value of our hydrogel technology for pain indications (arthritis, joint pain, etc.)
- Compared to the current market, NEXGEL's product demonstrated enhanced efficacy (faster-acting, longer lasting, with no mess)

Comparative In-Vitro¹ Human Skin Permeation of Diclofenac Sodium from NEXGEL Patch After 8 Hours



1. In-vitro skin permeation performed using full thickness derma to med human cadaver skin; 250 microns thick in Franz cells (3.65 ml volume with 0.95 cm² surface area) at 37°C. Receptor compartment contained pH 7.4 PBS. 4 cells per formulation sample. Sampling times at 2, 4, and 8 hours. Analysis by HPLC.
2. Skin samples were removed from Franz cell after 8 hours permeation experiment and extracted in ethanol for 12 hours at 37°C. Analysis by HPLC.

Consumer Health & Beauty

Bringing proven medical-grade technology to OTC and B&C for the first time through many new consumer products & applications

NEXGEL Branded Products

NOW PARABEN-FREE



NASDAQ: NXGL



“A little hexagon miracle! I felt immediate relief. I was astounded and will be a customer for life!”
~ Medagel Customer

M&A Strategy: Consumer Brand Acquisition

Kenkoderm Skincare Line

- Acquisition completed in December 2023
- Complimentary line of alternative psoriasis treatments
- Profitable (ttm) and immediately accretive
- 6 SKUs sold primarily DTC with significant portion of revenue derived from subscription bundles

Silly George Beauty Brand

- Acquisition completed in May 2024
- Specialty eye and eyelash consumer product line
- Annual run-rate of \$2mm when purchased, now over \$5mm
- Currently DTC and on Amazon
- Social media following: 89,000 Facebook and 86,000 Instagram followers + 254,000 active customer emails



Synergies support optimization of marketing and supply chain operations to drive revenue growth and margins

New marketing strategies and distribution channels in place to reach a wider consumer base

NASDAQ: NXGL



Cintas Corporation

Cintas is a leading provider of corporate identify uniforms, first aid and safety products and services to over 1 million businesses across North America

- Cintas will distribute SilverSeal, NEXGEL's hospital-grade dressing for wounds and burns to its customers in many sectors including hospitality and public service.
- This wound care solution will be available for employees of their customers.
- Partnership is significant for associated revenue, but also brand recognition awareness among this consumer demographic.
- The initial order of SilverSeal was successfully delivered to Cintas in the fourth quarter of 2024, leading to additional orders in Q1 '25.



NASDAQ: NXGL

13

A decorative graphic on the right side of the slide consisting of several overlapping, semi-transparent light blue geometric shapes, including triangles and quadrilaterals, arranged in a dynamic, abstract pattern.

STADA Arzneimittel AG

Partnership with European leader in consumer health supports expansion of NEXGEL OTC product portfolio

- STADA focuses on consumer healthcare products, generics and specialty pharm, selling products in approximately 120 countries across the world and this partnership will provide a path into North America.
- Mutually beneficial partnership to distribute and commercialize STADA consumer health OTC products in North America.
- First product together is Europe's #1 selling DAO enzyme supplement, Histasolv, a novel treatment for histamine food intolerance, which generates well over \$10 million in annualized revenue in Europe today.
- Generated revenue in Q4 '24.
- Signed amended agreement to launch another product in Q4 '25 and several more planned for '26 starting in Q1.



NASDAQ: NXGL

14

A decorative graphic on the right side of the slide consisting of several overlapping, semi-transparent light blue geometric shapes, including triangles and quadrilaterals, arranged in a dynamic, abstract pattern.

AbbVie (NYSE: ABBV)

CG Converting and Packaging is the exclusive supplier of gel pads to be used with AbbVie's Rapid Acoustic Pulse device for the improvement in the appearance of cellulite

- Allergan Aesthetics, acquired by AbbVie, purchased Soliton, the owner of the Resonic technology, for \$550 million in December 2021
- Leveraging NEXGEL's proprietary hydrogel technology, the gel pads are an important component and must be used FOR ALL body contouring device treatments
- In Q1 '24, received a non-refundable \$176,000 deposit from Abbvie against their first order



NASDAQ: NXGL


Reduction of Harmful Carcinogenic Plume from Laser Hair Removal

- *IRB study* in accordance with FDA designed to measure the efficacy of NEXGEL's hydrogel during laser hair removal in eliminating harmful particles or plume during treatments.
- 30-patient human trial at the Florida Clinical Research Center.
- Primary outcome measure is the reduction of harmful carcinogenic plume generated by laser hair removal into the air during procedures.
- Data publication shortly with commercial launch in 2025 upon meeting endpoint of study.
- Well over a dozen states have enacted legislation mandating the use of plume evacuation systems in order to mitigate hazards and risks of exposure to plume.



NASDAQ: NXGL

Revenue Growth / Record for FY '24 & Q4 '24



Highlights:

- Q4 2024 Revenue: \$3.04 million, +181% vs \$1.08 million for Q4 2023
- Full year 2024 Revenue: \$8.69 million, +112% vs \$4.09 million in 2023
- Over 100% full year and fourth quarter revenue growth year-over-year for third consecutive year
- revenue guidance of \$13 million for 2025 and expects to achieve positive EBITDA during the year
- As of 12/31/2024 cash totaled \$1.81 million
- As of March 24, 2025, 7,654,038 shares outstanding



NASDAQ: NXGL

Contact Us

Investor Relations:
 KCSA Strategic Communications
 Valter Pinto, Managing Director
 PH: (212) 896-1254
NEXGEL@KCSA.com



NASDAQ: NXGL